Spero Therapeutics
SPRO
38 hedge funds and large institutions have $10.9M invested in Spero Therapeutics in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 12 closing their positions.
250% more call options, than puts
Call options by funds: $7K | Put options by funds: $2K
1.05% less ownership
Funds ownership: 28.76% → 27.71% (-1%)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
24% less funds holding
Funds holding: 50 → 38 (-12)
33% less capital invested
Capital invested by funds: $16.1M → $10.9M (-$5.27M)
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.9K |
| 2 |
Squarepoint
New York
|
+$32K |
| 3 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$18.1K |
| 4 |
EWA
EP Wealth Advisors
Torrance,
California
|
+$13.9K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$12.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$142K |
| 2 |
Renaissance Technologies
New York
|
-$114K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$94.2K |
| 4 |
Jane Street
New York
|
-$54.5K |
| 5 |
VF
Virtu Financial
New York
|
-$47K |
SPRO Hedge Fund Activity: Q1 2025 in Review
38 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2025, worth a combined $10.9M — down 33% from $16.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of SPRO and 1 opened new positions — a net loss of 11 holders — while 10 trimmed existing stakes and 9 added.
The largest buyer was Geode Capital Management, adding an estimated $36.9K. The largest seller was Acadian Asset Management, cutting an estimated $142K.
- 38 institutional investors held Spero Therapeutics (SPRO) as of Q1 2025, down from 50 in Q4 2024.
- Funds reported $10.9M of Spero Therapeutics stock for Q1 2025, down 33% quarter-over-quarter.
- 1 fund opened new Spero Therapeutics positions in Q1 2025 and 12 closed out, a net change of -11 holders.
- The largest Spero Therapeutics buyer in Q1 2025 was Geode Capital Management, an estimated $36.9K added.
- The largest Spero Therapeutics seller in Q1 2025 was Acadian Asset Management, an estimated $142K sold.
Based on aggregated 13F filings for Q1 2025.